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Background: Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as analgesics and preventative
agents for vascular events. It is unclear whether their long-term use affects cancer risk. Data on the chemopreventative role of
these drugs on the risk of the upper aerodigestive tract cancer (UADT) are insufficient and mostly refer to oesophageal cancer.
The aim of this study was to investigate the effect of aspirin and other NSAIDs on the risk of UADT cancers.
Methods: A nested case–control study using the Primary Care Clinical Informatics Unit (PCCIU) database. Conditional logistics
regression was used for data analysis.
Results: There were 2392 cases of UADT cancer diagnosed between 1996 and 2010 and 7165 age-, gender- and medical practice-
matched controls from 131 general medical practices. Mean age of cases was 66 years (s.d. 12) and most were male (63%). Aspirin
was prescribed in a quarter of cases and controls, COX-2 inhibitors in 4% of cases and 5% of controls and other NSAIDs in 33% of
cases and 36% of controls. Aspirin prescription was associated with a nonsignificant risk reduction of cancer of UADT (adjusted
OR¼ 0.9, 95% CI¼ 0.8, 1.0), head and neck (HN; adjusted OR¼ 0.9, 95% CI¼ 0.7, 1.1) or the oesophagus (adjusted OR¼ 0.8, 95%
CI¼ 0.7, 1.0). Similar results were found for COX-2 inhibitors prescription. Prescription of other NSAIDs was associated with
significantly reduced risk of cancer of UADT (adjusted OR¼ 0.8, 95% CI¼ 0.7, 0.9), HN (adjusted OR¼ 0.8, 95% CI¼ 0.7, 0.9) and
the oesophagus (adjusted OR¼ 0.8, 95% CI¼ 0.7, 0.9). An increased volume of aspirin prescriptions was associated with a
significant risk reduction (test for trend Po0.001).
Conclusions: The decreased risk of cancer of the UADT associated with the use of non-COX-2 inhibitors, NSAIDs and long-term
aspirin therapy warrants further exploration of the benefits vs risks of the use of these agents.
Cancer of the upper aerodigestive tract (UADT; oral cavity,
pharynx, larynx and oesophagus combined) is, globally, the fourth
most common cancer and cause of cancer mortality, with an
estimated 1 033 004 incident cases and 712 489 deaths worldwide in
2008 (Ferlay et al, 2010). While a decrease in mortality was noted
in the European Union (EU) overall between 1993 and 2004, a
persistent rise was observed in central and eastern European
countries (Garavello et al, 2010).
Major risk factors for UADT cancer are tobacco consumption,
heavy alcohol drinking and poor nutrition, specifically lower fruit
and vegetable consumption (IARC Monographs on the Evaluation
of Carcinogenic Risks to Humans, 2004, 2010; Lagiou et al, 2009).
Other possible risk factors include poor oral hygiene, alcohol in
mouthwash and genetic factors (Warnakulasuriya, 2009).
Human papillomavirus (HPV) has been shown to have an
aetiological role in head and neck cancers (which include oral
cavity, oropharynx, hypopharynx and larynx) irrespective of
tobacco and alcohol use (Mork et al, 2001) and may be
responsible for the increase in incidence of oropharyngeal
squamous cell carcinoma (Mehanna et al, 2010) in the United
States between 1999 and 2006, United Kingdom between 1989
and 2006 whereas oropharyngeal cancer had the greatest rate of
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increase of any cancer in Scotland in 1987–2006 (Junor et al,
2010).
Recent analysis of individual patient data from randomised
clinical trials of daily aspirin (Rothwell et al, 2011) showed a
significant reduction in death due to cancer. Few studies have
investigated the role of non-steroidal anti-inflammatory drugs
(NSAIDs) specifically for UADT cancer (Bosetti et al, 2003; Friis
et al, 2006; Macfarlane et al, 2012) and the results are not
consistent. A recent systematic review of NSAIDs and aspirin use
and risk of head and neck cancer did not derive a definitive
conclusion, suggesting the need for further studies (Wilson et al,
2011).
The aim of this study was to investigate the effect of aspirin and
other NSAIDs use on the risk of UADT cancers. Specific objectives
were to investigate risk by cancer sub-site, duration of use and type
of NSAIDs.
MATERIALS AND METHODS
We conducted a nested case–control study using the Primary Care
Clinical Informatics Unit (PCCIU) (http://www.abdn.ac.uk/pcciu/)
database, which contained information from a sample of general
medical practices in Scotland.
The data set consists of complete copies of clinical data for all
registered patients. The UK National Health Service (NHS)
requires registration with a medical practice to access healthcare
services. At the time of data extraction, participating practices
systematically used electronic medical records for registration of
patients, morbidity recording and prescriptions. The current data
includes records up to October 2010 and covers around 15% of the
Scottish population. The data set included age, sex and socio-
economic status, and is representative of all the Scottish patients
(Elder et al, 2007).
Ethical permission was not required as the data were
anonymised and individuals could not be identified.
Cases and controls. Cases were defined as first time UADT cancer
cases (oral cavity, oropharynx, hypopharynx, larynx and oesopha-
gus) diagnosed in 1996 or later. Carcinoma in situ and cases aged
o18 years at diagnosis were excluded. We used all the available
eligible cases in the PCCIU database.
We aimed to identify three controls per case individually
matched by age (within 5 years), gender, medical practice and
duration of observation in the database, that is, controls should not
have follow-up observation time less than cases. In addition, period
of exposure considered for controls was truncated so that was not
systematically longer than that for the matched controls. Index
date for controls was selected from the date of diagnosis of
matching cases. Controls aged o18 years at index date were
excluded.
Both cases and controls with previous history of cancer were
excluded (Dregan et al, 2012).
Definition of exposure. We identified prescriptions of oral
aspirin, COX-2 inhibitors or other NSAIDs. Any prescriptions
before 1990 (because after 1990 the prescriptions were more likely
to have been generated electronically and therefore more complete
and reliable) and any prescriptions within a year before the
diagnosis or index date were disregarded. Topical NSAID
preparations were excluded. List of other NSAIDs is shown in
Appendix 1.
We defined patients as users if they had at least one
prescription. Age at first and last prescription, time between last
and first prescription, time between diagnosis and first and last
prescriptions and total number of prescriptions were obtained. We
also calculated the number of prescriptions per year as the total
number of prescriptions divided by time between the last and first
prescription.
Confounding factors. Additional data in the database were
available on age, gender and practice deprivation (Carstairs index;
Carstairs and Morris, 1989). Body mass index (BMI; at least 1 year
before the diagnosis/index date) was calculated from height and
weight, which were recorded in the database as well as self-reported
smoking status and alcohol consumption. Information was
obtained on previous history (at least 1 year before diagnosis/
index date) of coronary heart disease (CHD), atrial fibrillation
(AF), stroke and lipid-lowering medications. We also investigated
the family history of cancer.
Statistical analysis. Conditional logistic regression was used to
estimate odds ratios (ORs) with 95% confidence intervals (CIs).
Stratified analysis was conducted using logistic regression adjusted
for age, gender and clustering within practices. Crude ORs and
adjusted for the potential confounding variables listed above were
calculated. Continuous variables were categorised using median or
tertiles of the overall distribution. The w2-test was used for
comparison of proportions.
We investigated patterns of missing data and performed both
complete data analysis and analysis using multiple imputation
(MI). MI (n¼ 50 imputations) was performed using MI procedure
in STATA 13 (StataCorp LP, College Station, TX, USA, 2013) for
smoking, alcohol consumption and BMI with age, gender and
deprivation used in the imputation, separately for cases and
controls, using chained logit model. Briefly, MI is a simulation-
based approach for analysing incomplete data. MI procedure first
replaces missing values with multiple sets of simulated values to
complete the data, then applies standard analyses to each
completed data set, and finally adjusts the obtained parameter
estimates for missing-data uncertainty. The objective of MI is not
to predict missing values as close as possible to the true ones but to
handle missing data in a way resulting in valid statistical inference
(Marchenko, 2011).
Propensity score was used to reduce the impact of selection bias
and confounding. Briefly, propensity score is the probability of
treatment assignment conditional on observed baseline character-
istics (Austin, 2011). The propensity score allows analysis of
observational (nonrandomised) studies so that it mimics some of
the particular characteristics of a randomised controlled trial. Out
of four available methods (matching on the propensity score,
stratification on the propensity score, inverse probability of
treatment weighting using the propensity score, and covariate
adjustment using the propensity score) the inverse probability of
aspirin treatment weighting was used. Propensity score (probability
that patients had received aspirin prescription) was calculated from
logistic regression model with aspirin prescription as outcome and
potential confounding factors as predictors. Weight in the model
for patients prescribed aspirin was the inverse of the propensity
score values whereas the weight for patients not receiving aspirin
prescription was the inverse of (1 the propensity score).
Analysis was conducted using IBM SPSS Statistics version 21
(IBM Corp., Released 2012, Armonk, NY, USA) and STATA 13.
RESULTS
We identified 2392 cases of UADT cancer (1195 of HNC and 1197
oesophageal cancer) and 7165 controls from 131 general medical
practices between 1996 and 2010. The majority (2381) of cases had
three matched controls and 11 cases had two controls. Mean age of
cases was 66 years (s.d. 12) and most were male (67%).
The proportion of incomplete data for BMI, smoking and
alcohol was 43%, 24% and 35% respectively among cases and 38%,
23% and 34% respectively among controls. Complete data were
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available for 1201 (50%) of cases and 3862 (54%) of controls.
Among cases, complete data were available for 48% of HNC cases
and for 52% of oesophageal cancer cases. Overall, there was
no significant difference in data completeness by gender
(w2 P¼ 0.511), however, there was variation by age group
(Po0.001) with the highest proportion of complete data in
66–75 years age group (57%) and the lowest in 18–55 age group
(47%). There was a significant difference in data completeness by
deprivation (Po0.001) with the highest completeness proportion
in the highest deprivation category (59%). There was a significant
difference (Po0.001) in data availability by stroke (65% vs 53%),
CHD (67% vs 51%), aspirin prescription (71% vs 47%), COX-2
inhibitors (76% vs 52%) and other NSAIDs (68% vs 45%; data not
shown).
Deprivation was strongly related to risk of UADT cancer
(Table 1; OR¼ 2.3, 95% CI¼ 1.6, 3.2) in most deprived category
compared with least deprived; test for trend Po0.001. Lower BMI
was associated with increased risk of UADT cancer (OR¼ 2.6, 95%
CI¼ 1.5, 4.3) in patients with BMI¼ 15.5–18.4 compared with
BMI¼ 30–54; test for trend Po0.001. Individuals categorised as
‘ever smokers’ had a significantly higher risk of UADT cancer
compared with ‘never smokers’ (Table 1; OR¼ 2.4, 95% CI¼ 2.1,
2.7). Individuals with a high level of alcohol consumption
(OR¼ 1.7; 95% CI¼ 1.4, 2.1) were at greater risk of UADT cancer
than low or non-alcohol consumers. History of CHD and stroke
was associated with increased UADT cancer risk: OR¼ 1.2, 95%
CI¼ 1.0, 1.4 and OR¼ 1.4, 95% CI¼ 1.1, 1.8, respectively. No
association was found for history of AF (OR¼ 1.0, 95% CI¼ 0.8,
1.3), family history of cancer (OR¼ 1.1; 95% CI¼ 0.8, 1.5) or lipid-
lowering drug prescription (OR¼ 1.0; 95% CI¼ 0.9, 1.2; Table 1).
Aspirin was prescribed in a quarter of cases and controls,
COX-2 inhibitors were prescribed in 4% of cases and 5% of
controls and other NSAIDs were prescribed in 33% of cases and
36% of controls (Table 2). Aspirin prescription was associated with
nonsignificant reduction in risk of cancer of UADT (adjusted
OR¼ 0.9, 95% CI¼ 0.8, 1.0), HN (adjusted OR¼ 0.9, 95%
CI¼ 0.8, 1.2) and oesophagus (adjusted OR¼ 0.9, 95% CI¼ 0.7,
1.1; Table 2). Similar results were found for COX-2 inhibitors
prescriptions. Prescription of other NSAIDs was associated with
reduced risk of cancer of UADT (adjusted OR¼ 0.8, 95% CI¼ 0.7,
0.9), HN (adjusted OR¼ 0.8, 95% CI¼ 0.7, 0.9) and the
oesophagus (adjusted OR¼ 0.8; 95% CI¼ 0.7, 0.9; Table 2). There
was no significant difference in the above OR estimates between
cancer of the head and neck and oesophagus (P40.05; Table 2),
therefore, these two sites were combined.
Aspirin prescription was significantly associated with older age,
deprivation, BMI, smoking, alcohol consumption, history of CHD,
AF, stroke and lipid-lowering drug prescription (Po0.001; data
not shown in tables).
Further analysis of aspirin prescription (ever) showed no change
in OR estimates when weighting by propensity score was used in
the model (for UADT cancer OR¼ 0.9; 95% CI¼ 0.7, 1.0). Using
multiple imputation and additional adjustment for BMI, smoking
and alcohol consumption resulted in similar estimate (OR¼ 0.9;
95% CI¼ 0.8, 1.0; data not shown in tables).
When considering patients with complete data only, aspirin
prescriptions were not associated with decreased risk of UADT
cancer (OR¼ 1.0, 95% CI¼ 0.9, 1.2).
There was a significant reduction associated with aspirin
prescriptions for females (OR¼ 0.7, 95% CI¼ 0.6, 0.9) but not
for males (OR¼ 1.0, 95% CI¼ 0.9, 1.2; test for heterogeneity
P¼ 0.019; Table 3). There were no differences in OR estimates for
aspirin by age, deprivation, BMI, smoking or alcohol (test for
heterogeneity P40.05; Table 3), however, significant risk reduction
associated with aspirin prescriptions was observed among patients
with missing data for BMI, smoking and alcohol (Table 3). There
was no difference in estimates between males and females when
multiple imputation and propensity score were used (P40.05, data
not shown in tables).
There was no significant reduction associated with UADT
cancer risk for age at first and last aspirin prescription, time
between last and first prescription, time between diagnosis and
first and last prescription and number of prescriptions per year
(Table 4). However there was a significant decrease in risk of
UADT cancer with increased number of prescriptions (OR¼ 0.8,
95% CI¼ 0.6, 0.9) in those with total number of prescription
between 29 and 147 compared with never prescription, test for
trend P¼ 0.017 (Table 4). This result was not significant when
analysed separately for cancer of the head and neck and
oesophageal cancer (OR¼ 0.77, 95% CI¼ 0.5, 1.1 and
OR¼ 0.81, 95% CI¼ 0.6, 1.1, respectively; data not shown in
tables).
DISCUSSION
This first large Scotland-based general practice-derived
case–control study showed a decrease in risk of UADT cancer
with a high volume of aspirin prescriptions, that is,429, as well as
with the prescription of other NSAIDs (not COX-2 inhibitors). The
majority of the UK population is registered with a general medical
practice; therefore these results are likely to be representative of the
general population.
While our study overall did not show a significant association
between ever aspirin prescription and risk of UADT cancer, when
considered by total number of prescriptions, aspirin was associated
with a reduced risk of UADT cancer for high total number of
prescriptions and ever use of other NSAIDs. This finding supports
results of a review of aspirin and cancer risk (Wilson et al, 2011),
which showed that aspirin use was associated with a reduced risk
of cancer of the oesophagus and multicentre study of UADT
cancer, which showed that regular aspirin use (at least once a week
for a year) was not associated with risk of UADT cancer overall but
was associated with a reduced risk for cancer of oesophagus
(OR¼ 0.5, 95% CI¼ 0.3–0.9), hypopharynx (OR¼ 0.5, 95%
CI¼ 0.3–1.0) and larynx (OR¼ 0.7, 95% CI¼ 0.5–1.0;
Macfarlane et al, 2012).
Analysis of individual patient data from eight randomised trials
of daily aspirin vs no aspirin (Rothwell et al, 2011) showed a
significant reduction in death due to cancer (OR¼ 0.8, 95%
CI¼ 0.7, 0.9). There were no data reported specifically on head and
neck cancer, but there was a nonsignificant decrease in risk of
death due to oesophageal cancer (hazard ratio (HR)¼ 0.8 (95%
CI¼ 0.3, 2.2) for 0–5 years of follow-up and HR¼ 0.43 (95%
CI¼ 0.1, 1.7) for 5 years follow-up or longer). The overall
protective effect of aspirin was more evident for adenocarcinomas
(HR¼ 0.5, 95% CI¼ 0.4, 0.8 for 5 years of follow-up or longer).
The protective effect of aspirin in this combined analysis did not
appear to increase at doses 475mg daily.
Biologically, aspirin and other NSAIDs suppress the production
of prostaglandins and thromboxanes by irreversible inactivation of
the cyclooxygenase (COX) enzyme which is involved in the
mechanism of carcinogenesis (Thun et al, 2002). Other mechan-
isms include the induction of apoptosis through COX-independent
pathways, the inhibition of NFjb factor and the upregulation of
tumour suppression genes (Herna´ndez-Dı´az and Garcı´a Rodrı´guez,
2007).
We have evaluated aspirin and other NSAIDs separately and
found stronger chemopreventive effect of other NSAIDs for both
HNC and oesophageal cancer. It was suggested that different types
of NSAIDs might have different effects due to residual confound-
ing and biological mechaisms (Herna´ndez-Dı´az and Garcı´a
Rodrı´guez, 2007; Vinogradova et al, 2011).
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With respect to methodological quality, the study included
cancers over several sites in the UADT. No information was
available regarding the histological subtype or cancer stage. While
these are a heterogeneous group of neoplasms, they have similar
aetiologies: regular alcohol consumption and tobacco smoking
(Lagiou et al, 2009; IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans, 2010). To investigate potential
aetiological differences, we conducted additional analyses
separately for head and neck cancer and cancer of the oesophagus
and did not find significant differences in risk estimates.
Matching controls on sex, age, medical practice and index date
removed effects from these confounding factors.
NSAID exposure was measured in terms of prescriptions issued.
In the current study we did not have information on dose or
indication for use of aspirin or other NSAIDs. The issue of a
prescription does not mean that the medicine was actually used.
Table 1. Relationship between socioeconomic, behavioural and medical factors and risk of UADT cancer
Characteristics
Cases
n¼2392
N (%)
Controls
n¼7176
N (%)
OR (95% CI)a
Test for trend P-value
Carstairs deprivation category
1 (Least deprived) 94 (3.9) 365 (5.1) 1.00
2 199 (8.3) 665 (9.3) 1.19 (0.85, 1.67)
3 404 (16.9) 1356 (18.9) 1.20 (0.89, 1.61)
4 785 (32.8) 2294 (32.0) 1.56 (1.18, 2.06)
5 380 (15.9) 1043 (14.6) 1.73 (1.28, 2.34)
6 259 (10.8) 738 (10.3) 1.80 (1.30, 2.51)
7 (Most deprived) 271 (11.3) 704 (9.8) 2.26 (1.59, 3.22)
Po0.001
Body mass index
30.0–54.0 260 (19.1) 1051 (23.7) 1.00
25.0–29.9 520 (38.1) 1832 (41.4) 1.13 (0.94, 1.35)
18.5–24.9 552 (40.4) 1498 (33.8) 1.42 (1.18, 1.71)
15.5–18.4 33 (2.4) 49 (1.1) 2.55 (1.52, 4.28)
Missing 1027 2735 Po0.001
Smoking
Never 453 (24.9) 2411 (43.7) 1.00
Ever 1370 (75.1) 3109 (56.3) 2.40 (2.10, 2.73)
Missing 569 1645
Alcohol consumption
No 329 (21.1) 1033 (21.8) 1.00
Low (within recommended limits) 884 (56.8) 3057 (64.6) 0.89 (0.75, 1.04)
High (above recommended limits) 344 (22.1) 645 (13.6) 1.70 (1.37, 2.11)
Missing 835 2430
Coronary heart disease (at least 12 months before diagnosis/index date)
No 2007 (83.9) 6156 (85.9) 1.00
Yes 385 (16.1) 1009 (14.1) 1.18 (1.04, 1.35)
Atrial fibrillation (at least 12 months before diagnosis/index date)
No 2305 (96.4) 6911 (96.4) 1.00
Yes 87 (3.6) 254 (3.6) 1.02 (0.80, 1.32)
Stroke (at least 12 months before diagnosis/index date)
No 2293 (95.9) 6946 (96.9) 1.00
Yes 99 (4.1) 219 (3.1) 1.38 (1.08, 1.76)
Family history of cancer
No 2341 (97.9) 7020 (98.0) 1.00
Yes 51 (2.1) 145 (2.0) 1.06 (0.76, 1.48)
Lipid-lowering drug prescription (at least 12 months before diagnosis/index date)
Never 1943 (81.2) 5832 (81.4) 1.00
Ever 449 (18.8) 1333 (18.7) 1.01 (0.89, 1.15)
Abbreviations: CI¼ confidence interval; OR¼odds ratio; UADT¼ upper aerodigestive tract cancer.
aFrom conditional logistic regression (unadjusted).
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Questionnaire-based study conducted in UK general medical
practices which compared prescribed NSAIDs and described by
patients reported mean (s.d.) compliance (percentage of intended
dose taken) of 0.73 (0.55) for ibuprofen, 0.76 (0.56) for diclofenac
and 0.76 (0.55) for Naproxen (Hawkey et al, 2000). It is unlikely,
however, that non-adherence would differ systematically between
cases and controls in our study.
The results will not have been influenced by recall bias because
prescriptions were recorded prospectively before the index date.
No data were available regarding the use of over-the-counter
medications, which contain aspirin and NSAIDs, and this will have
underestimated exposure to these medicines. COX-2 inhibitors can
only be obtained by prescription in the UK. However the reported
prevalence of aspirin prescription is comparable to prevalence of
self-reported aspirin use in other studies conducted in the UK
(Macfarlane et al, 2012; 22% in cases and 26% in controls).
Herna´ndez-Dı´az and Garcı´a Rodrı´guez (2007) in the study of
NSAIDs and risk of lung cancer performed a sensitivity analysis to
quantify the impact of misclassification due to unrecorded over-
the-counter use or to noncompliance. They concluded that the
protective effect could not be explained by the unrecorded use.
Yood et al (2007) concluded from their sensitivity analysis that
prescription data can give valid estimates of association even
though some of the drugs are available over the counter.
Prescriptions for cases before diagnosis could relate to early
cancer symptoms before the recorded diagnosis. However we
excluded any prescriptions within 1 year of diagnoses.
We defined ever users as those with at least one prescription.
Another study of prescriptions (Vinogradova et al, 2011) similarly
defined users as those with at least one prescription, whereas Friis
et al (2006) defined users as those with two or more prescriptions.
Studies which collected information using questionnaires defined
users as those who ever took aspirin before the onset of illness
(Jayaprakash et al, 2006) or as regular users (use at least once a
week for a year; Macfarlane et al, 2012). In our study, among ever
users cases and controls, there were 11% and 12% with only one
prescription, respectively. Defining users as those with at least two
prescriptions resulted in adjusted OR of 0.87 (0.78, 1.55) which is
similar to our estimates when users were defined as those with at
least one prescription.
We adjusted for potential confounders such as deprivation,
BMI, smoking, alcohol consumption, medical history and family
history of cancer. However the quality of some of this information
was poor. For example, there was a large amount of missing data
and inconsistency in recording of smoking and alcohol consump-
tion. In addition, we did not have information on other risk factors
for UADT, such as poor nutrition (especially low fruit and
vegetable consumption), history of HPV infection, poor oral
hygiene and genetic factors. However, analyses of US healthcare
utilisation data sets indicate that these potential confounders have
limited influence in studies of NSAID use and various health
outcomes (Schneeweiss et al, 2005). Analysis of the relationship
between confounding factors and UADT cancer in our study
showed similar association. For example, increased risk was
associated with increased deprivation (Conway et al, 2010), low
BMI (Gaudet et al, 2010), smoking (IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans, 2004) and alcohol
consumption (IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans, 2010). We also used multiple
imputation to replace the missing values for confounding factors.
Systematic review of observation studies of NSAIDs use and
upper gastrointestinal tract bleeding and perforation (Herna´ndez-
Dı´az and Rodrı´guez, 2000) showed an increased pooled relative
risk of 3.8 (95% CI¼ 3.6, 4.1). However Rothwell et al (2012) in the
study of individual patient data from 51 randomised trials of short-
term effects of daily aspirin on cancer incidence, mortality and
non-vascular death showed that the reduced risk of major vascular
events was initially offset by an increased risk of major bleeding,
but effects on both outcomes diminished with increasing follow-
up, leaving only the reduced risk of cancer from 3 years onwards.
Case-fatality from major extracranial bleeds was also lower on
aspirin than on control (OR¼ 0  32, 95% CI¼ 0  12–0  83).
The incidence of oral cancer is increasing in many countries
(Jemal et al, 2010; Chaturvedi et al, 2013) and the lack of efficient
therapy and the considerable associated morbidity and mortality
make chemoprevention a realistic possibility (Jemal, 2012),
particularly since this might be targeted to high-risk individuals
with leukoplakia or other precursor lesions (Nelson, 2006).
NSAIDs have shown promise as chemopreventive agents for oral
cancer in experimental studies (Goodin and Shiff, 2004). Further
Table 2. NSAID prescription and UADT cancer risk
All UADT cancers Head and Neck cancer Oesophageal cancer
Prescription
Cases
n¼2392
N (%)
Controls
n¼7165
N (%)
OR
(95% CI)a
Cases
n¼1195
N (%)
Controls
n¼3580
N (%)
OR
(95% CI)a
Cases
n¼1197
N (%)
Controls
n¼3585
N (%)
OR
(95% CI)a P-valueb
Aspirin
Never 1798 (75.2) 5397 (75.3) 1.00 936 (78.3) 2862 (79.9) 1.00 862 (72.0) 2535 (70.7) 1.00
Ever 594 (24.8) 1768 (24.7) 0.90 (0.78, 1.04) 259 (21.7) 718 (20.1) 0.93 (0.76, 1.15) 335 (28.0) 1050 (29.3) 0.87 (0.72, 1.05) 0.122
COX-2
Never 2289 (95.7) 6783 (94.7) 1.00 1150 (96.2) 3403 (95.1) 1.00 1139 (95.2) 3380 (94.3) 1.00
Ever 103 (4.3) 382 (5.3) 0.84 (0.67, 1.06) 45 (3.8) 177 (4.9) 0.80 (0.56, 1.13) 58 (4.9) 205 (5.7) 0.88 (0.64, 1.21) 0.620
Other NSAID
Never 1612 (67.4) 4563 (63.7) 1.00 817 (68.4) 2314 (64.6) 1.00 795 (66.4) 2249 (62.7) 1.00
Ever 780 (32.6) 2602 (36.3) 0.83 (0.75, 0.93) 378 (31.6) 1266 (35.4) 0.82 (0.70, 0.96) 402 (33.6) 1336 (37.3) 0.84 (0.73, 0.98) 0.825
Abbreviations: CHD¼ coronary heart disease; CI¼ confidence interval; COX-2¼ cyclooxygenase-2; HNC¼head and neck cancer; NSAID¼ non-steroidal anti-inflammatory drug; OR¼odds
ratio; UADT¼ upper aerodigestive tract cancer.
aFrom conditional logistic regression adjusted for deprivation, CHD, stroke, aspirin, COX-2 inhibitors and other NSAID.
bP-value to test the null hypothesis of no difference in estimates between HNC and oesophageal cancer.
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exploration of the benefits vs risks of the use of these agents is
needed.
CONCLUSION
There is evidence of decreased risk of UADT cancer associated
with the use of NSAIDs (non-COX-2 inhibitors) and number of
aspirin prescriptions. These findings are important and should be a
priority for further investigation using major studies and other data
sources.
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Table 3. Aspirin use and UADT cancer risk by demographic and
behavioural factors
Characteristics
OR (95% CI)
Test for heterogeneity
P-value
Gender
M 1.02 (0.86, 1.22)a
F 0.72 (0.56, 0.91)
P¼0.019
Age (years)
18–55 0.78 (0.46, 1.32)b
56–65 0.91 (0.68, 1.21)
66–75 0.96 (0.77, 1.19)
76þ 0.81 (0.64, 1.02)
P¼0.269
Carstairs deprivation category
1 (Least deprived) 0.90 (0.45, 1.77)
2 0.86 (0.53, 1.41)b
3 0.94 (0.69, 1.40)
4 0.87 (0.68, 1.10)
5 0.77 (0.55, 1.08)
6 1.14 (0.78, 1.69)
7 (Most deprived) 0.85 (0.57, 1.27)
P¼0.438
Body mass index
30.0–54.0 1.08 (0.77, 1.50)b
25.0–29.9 1.32 (1.02, 1.71)
18.5–24.9 0.88 (0.66, 1.17)
15.5–18.4 0.75 (0.13, 4.26)
P¼ 0.164
Missing 0.65 (0.51, 0.84)
Smoking
Never 1.00 (0.76. 1.32)b
Ever 0.88 (0.74, 1.05)
P¼ 0.108
Missing 0.54 (0.37, 0.79)
Alcohol consumption
No or low(within recommended limits) 0.97 (0.82, 1.15)b
High (above recommended limits) 0.92 (0.62, 1.37)
P¼ 0.978
Missing 0.74 (0.56, 0.97)
Abbreviations: CHD¼ coronary heart disease; CI¼ confidence interval; F¼ female;
M¼male; NSAID¼ non-steroidal anti-inflammatory drug; OR¼odds ratio; UADT¼ upper
aerodigestive tract cancer.
aFrom conditional logistic regression adjusted for deprivation, CHD, stroke and other
NSAIDs.
bFrom unconditional logistic regression adjusted for age, gender, deprivation, CHD, stroke
and other NSAIDs taking into account aggregation within medical practices.
Table 4. Aspirin prescription and UADT cancer risk
Characteristicsa
Cases
n¼2392
N (%)
Controls
n¼7165
N (%)
OR
(95% CI)b
Test for
trend
(P-value)
Age at first prescription (years)
Never 1798 (75.2) 5397 (75.3) 1.00 0.112
26–61 181 (7.6) 539 (7.5) 0.84 (0.68, 1.04)
62–70 216 (9.0) 625 (8.7) 0.90 (0.74, 1.09)
71–93 197 (8.2) 604 (8.5) 0.87 (0.70, 1.08)
Age at last prescription (years)
Never 1798 (75.2) 5397 (75.3) 1.00 0.185
27–66 176 (7.4) 577 (8.0) 0.76 (0.62, 0.93)
67–74 210 (8.8) 557 (7.8) 1.05 (0.85, 1.28)
75–98 208 (8.7) 634 (8.9) 0.84 (0.67, 1.05)
Time between last and first prescription (years)
Never 1798 (75.2) 5397 (75.3) 1.00 0.102
o1.5 187 (7.8) 586 (8.2) 0.86 (0.71, 1.04)
1.6–5.3 203 (8.5) 591 (8.3) 0.89 (0.73, 1.09)
5.4–19.2 204 (8.5) 591 (8.3) 0.86 (0.69, 1.06)
Time between diagnosis and first prescription (years)
Never 1798 (75.2) 5397 (75.3) 1.00 0.061
1–3 199 (8.3) 574 (8.0) 0.91 (0.75, 1.09)
4–6 159 (6.6) 497 (7.0) 0.84 (0.68, 1.04)
7–20 236 (9.9) 697 (9.7) 0.85 (0.70, 1.04)
Time between diagnosis and last prescription (years)
Never 1798 (75.2) 5397 (75.3) 1.00 0.300
41 445 (18.6) 1365 (19.1) 0.83 (0.71, 0.97)
2–14 149 (6.2) 403 (5.6) 0.99 (0.81, 1.23)
Total number of prescriptions
Never 1798 (75.2) 5397 (75.3) 1.00 0.017
1–7 202 (8.4) 571 (8.0) 0.95 (0.79, 1.15)
8–28 198 (8.3) 603 (8.4) 0.83 (0.68, 1.01)
29–147 194 (8.1) 594 (8.3) 0.79 (0.64, 0.99)
Average number of prescriptions per yearc
Never 1798 (75.2) 5397 (75.3) 1.00 0.122
0.4–4 155 (6.5) 443 (6.2) 0.88 (0.70, 1.09)
5–7 207 (8.7) 642 (9.0) 0.82 (0.67, 1.00)
8–40 232 (9.7) 683 (9.5) 0.90 (0.75, 1.07)
Abbreviations: BMI¼body mass index; CHD¼ coronary heart disease; CI¼ confidence
interval; F¼ female; M¼male; OR¼odds ratio; UADT¼ upper aerodigestive tract cancer.
aCategories created from continuous variable using median or tertiles of the overall
distribution.
bFrom conditional logistic regression adjusted for deprivation, BMI (o25), smoking (ever),
alcohol consumption (high), CHD, stroke.
cTotal number of prescriptions divided by time between last and first prescription.
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APPENDIX 1
Aceclofenac Lederfen
Acemetacin Lodine
Arthrotec Mefenamic acid
Azapropazone Meloxicam
Brexidol Mobic
Brufen Mobiflex
Caprin Motifene
Clinoril Motrin
Co-codaprin Nabumetone
Codafen continus Napratec
Dexketoprofen Naprosyn
Diclofenac Naproxen
Diclomax Nycopren
Diflunisal Oruvail
Dolobid Piroxicam
Etodolac Ponstan
Feldene Preservex
Fenbid Relifex
Fenbufen Rheumox
Fenoprofen Rhumalgan CR
Flurbiprofen Sulindac
Froben Surgam
Froben-p42 Synflex
Ibuprofen Tenoxicam
Indomax SR Tiaprofenic acid
Indometacin Volsaid retard
Keral Voltarol
Ketoprofen
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